Development of personalized medicine for cancer chemotherapy according to a variety of sensitivity and pharmacokinetics
Project/Area Number |
21590167
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Single-year Grants |
Section | 一般 |
Research Field |
Medical pharmacy
|
Research Institution | Kumamoto University |
Principal Investigator |
HAMADA Akinobu 熊本大学, 医学部附属病院, 准教授 (00322313)
|
Co-Investigator(Kenkyū-buntansha) |
SAITO Hideyuki 熊本大学, 医学部附属病院, 教授 (40225727)
佐々木 治一郎 熊本大学, 大学院・生命科学研究部, 助教 (60419637)
川口 辰哉 熊本大学, 医学部附属病院, 准教授 (50244116)
|
Co-Investigator(Renkei-kenkyūsha) |
SASAKI Ji-i 北里大学, 医学部, 准教授 (60419637)
KAWAGUCHI Tatsuya 熊本大学, 医学部附属病院, 准教授 (50244116)
|
Research Collaborator |
ANDO Yuichi 名古屋大学, 医学部附属病院, 准教授 (10360083)
|
Project Period (FY) |
2009 – 2011
|
Project Status |
Completed (Fiscal Year 2011)
|
Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2011: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2010: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2009: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
|
Keywords | オーダーメード医療 / 分子標的薬 / 癌 / 薬剤反応性 |
Research Abstract |
Objectives : We analyzed the association of ABCB1 polymorphisms with erlotinib-induced toxicity and the pharmacokinetics in patients with non-small cell lung cancer. Methods : After erlotinib 150 mg was administered to 50 patients, ABCB1 polymorphisms were analyzed via either TaqMan assays or direct nucleotide sequencing. Plasma concentrations were measured by high-performance liquid chromatography. Results : The trough concentration at steady state(Css) in patients with the ABCB1 1236TT-2677TT-3435TT genotype was higher as compared to others groups(P=0. 021) and this patients carrying this genotype had a higher risk of development for higher grade 2 toxicity(p=0. 012). Conclusion : The present study suggested that the ABCB1 1236TT-2677TT-3435TT genotype was associated with higher concentration and the risk of development for higher toxicity in patients treated with erlotinib.
|
Report
(4 results)
Research Products
(57 results)
-
-
-
[Journal Article] Association of ABCB1 polymorphisms with erlotinib pharmacokinetics and toxicity in Japanese patients with non-small cell lung cancer2012
Author(s)
Hamada A, Sasaki J, Saeki S, Iwamoto N, Inaba M, Ushijima S, Urata M, Kishi H, Fujii S, Semba H, Kashiwabara K, Tsubata Y, Kai Y, Isobe T, Kourogi H, Saito H
-
Journal Title
Pharmacogenomics
Volume: 13
Pages: 615-624
Related Report
Peer Reviewed
-
-
-
-
-
-
-
-
-
[Journal Article] Erlotinib efficacy and cerebrospinal fluid concentration in lung adenocarcinoma patients developing leptomeningeal metastases during gefitinib therapy2011
Author(s)
Masuda T, Hattori N, Hamada A, Iwamoto H, Ohshimo S, Kanehara M, Ishikawa N, Fujitaka K, Haruta Y, Murai H, Kohno N
-
Journal Title
Cancer Chemother Pharmacol
Volume: 67
Pages: 1465-1469
Related Report
Peer Reviewed
-
-
-
-
-
-
-
-
-
-
-
-
-
[Journal Article] Relationship between an effective dose of imatinib, body surface area, and trough drug levels in patients with chronic myeloid leukemia2009
Author(s)
K awaguchi T, Hamada A, Hirayama C, Nakashima R, Nambu T, Yamakawa Y, Watanabe H, Horikawa H, Mitsuya H, Saito H
-
Journal Title
Int J Hematol
Volume: 89
Pages: 642-8
NAID
Related Report
Peer Reviewed
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-